Primary Endocrine Therapy vs Surgery in Older ER-Positive Breast Cancer: Biology Defines Candidates
This meta-analysis pools six tamoxifen-era trials and maps 23 observational cohorts to show that tumor biology and competing mortality, not age alone, should drive selection for primary endocrine therapy in older women.
📅 Journal publication: Nov 2, 2026·Last updated: Nov 10, 2026
No survival difference found between endocrine therapy and surgery in older breast cancer patients.
Identifying appropriate treatment strategies for older women with estrogen receptor-positive breast cancer is crucial for optimizing outcomes. Primary endocrine therapy (pET) and surgery showed no significant difference in overall survival for these patients (HR, 1.14; 95% CI, 0.98-1.33). Study suggests considering tumor biology and frailty, rather than age alone, to determine candidacy for pET. Limitations include heterogeneity across trials. Consider tumor biology and frailty, not just age, for pET candidacy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Carleton N, Zou J, Mu Y, Oesterreich S, Puhalla S, Foldi J, Tseng G, Lee AV, McAuliffe PF
Citation:Carleton N, Zou J, Mu Y, et al. Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis. JAMA network open. 2026;9(11):e2643218. doi:10.1001/jamanetworkopen.2026.43218